This double-blind, controlled, randomized, three-way cross-over study evaluates the effect of 40 g (D1 group) and 20 g (D2 group) of acacia gum (AG) versus no treatment (NT group) on post-prandial glucose (PPG) levels...This double-blind, controlled, randomized, three-way cross-over study evaluates the effect of 40 g (D1 group) and 20 g (D2 group) of acacia gum (AG) versus no treatment (NT group) on post-prandial glucose (PPG) levels in normal-weight and overweight subjects. Additionally, post-prandial insulin (PPI) levels as well as the safety and tolerability of gum acacia were assessed. 35 healthy subjects aged 25 - 60 years, body mass index 18.5 kg/m<sup>2</sup> - 29.9 kg/m<sup>2</sup>, received one treatment of 20 g, 40 g, or 0 g of AG each. Glucose and insulin values were determined at -15 min and prior to the intake (time “0”) as well as 15, 30, 45, 60, 90 120, and 180 min after the “0 min” blood draw. The mean PPG levels were lower (34% in D1 group, p = 0.003;35% in D2 group, p = 0.005) than in the NT group. PPI concentration was statistically significantly lower at all time points except baseline in both treatment groups compared to NT groups. Global benefit and tolerability were rated as “very good” or “good” by 100% of subjects in the treatment groups. This study provides robust evidence of the significant benefits of AG consumption on PPG and PPI levels in healthy subjects. Moreover, very good tolerability was demonstrated.展开更多
For type 1 and advanced type 2 diabetic patients, insulin replacement therapy with simulating on-demand prandial and basal insulin secretion is the best option for optimal glycemic control. However, there is no insuli...For type 1 and advanced type 2 diabetic patients, insulin replacement therapy with simulating on-demand prandial and basal insulin secretion is the best option for optimal glycemic control. However, there is no insulin delivery system yet could mimic both controlled basal insulin release and rapid prandial insulin release in response to real-time blood glucose changes. Here we reported an artificial insulin delivery system, mimicking physiological basal and prandial insulin secretion, to achieve real-time glycemic control and reduce risk of hypoglycemia. A phenylboronic acid(PBA)/galactosyl-based glucose-responsive insulin delivery system was prepared with insulin-loaded micelles embedded in hydrogel matrix. At the hyperglycemic state, both the hydrogel and micelles could swell and achieve rapid glucose-responsive release of insulin, mimicking prandial insulin secretion.When the glucose level returned to the normal state, only the micelles partially responded to glucose and still released insulin gradually. The hydrogel with increased crosslinking density could slow down the diffusion speed of insulin inside, resulting in controlled release of insulin and simulating physiological basal insulin secretion. This hydrogel-micelle composite insulin delivery system could quickly reduce the blood glucose level in a mouse model of type 1 diabetes, and maintain normal blood glucose level without hypoglycemia for about 24 h. This kind of glucose-responsive hydrogel-micelle composite may be a promising candidate for delivery of insulin in the treatment of diabetes.展开更多
目的 分析德谷门冬双胰岛素、基础-餐时胰岛素短期强化治疗对新诊断2型糖尿病(T2DM)患者血糖控制的影响。方法 选取60例新诊断T2DM患者为研究对象,依据随机数字法分为对照组(30例,德谷门冬双胰岛素治疗)、研究组(30例,基础-餐时胰岛素...目的 分析德谷门冬双胰岛素、基础-餐时胰岛素短期强化治疗对新诊断2型糖尿病(T2DM)患者血糖控制的影响。方法 选取60例新诊断T2DM患者为研究对象,依据随机数字法分为对照组(30例,德谷门冬双胰岛素治疗)、研究组(30例,基础-餐时胰岛素短期强化治疗)。对比两组患者的血糖指标[糖化血红蛋白(HbA1c)、空腹血糖(FPG)和餐后2 h血糖(2 h PBG)],血糖控制情况(血糖达标时间、血糖波动水平)和低血糖发生率,治疗效果。结果 两组治疗前HbA1c、FPG和2 h PBG水平对比无显著差异(P>0.05);治疗后,研究组HbA1c(6.08±0.76)%、FPG(5.71±0.59)mmol/L和2 h PBG(7.53±0.96)mmol/L比对照组的(8.19±1.14)%、(6.86±0.84)mmol/L、(9.38±1.33)mmol/L低,差异具有统计学意义(P<0.05)。研究组患者血糖达标时间为(6.95±1.61)d、血糖波动为(2.25±0.35)mmol/L、夜间低血糖发生率为0;对照组患者血糖达标时间为(8.26±1.56)d、血糖波动为(3.12±0.68)mmol/L、夜间低血糖发生率为20.00%;研究组患者的血糖达标时间、血糖波动水平和低血糖发生率均显著低于对照组,差异具有统计学意义(P<0.05)。研究组患者的治疗总有效率(100.00%)显著高于对照组(80.00%),差异具有统计学意义(P<0.05)。结论 对于新诊断T2DM患者来说,基础-餐时胰岛素短期强化治疗相对于德谷门冬双胰岛素疗效较好,值得推广。展开更多
文摘This double-blind, controlled, randomized, three-way cross-over study evaluates the effect of 40 g (D1 group) and 20 g (D2 group) of acacia gum (AG) versus no treatment (NT group) on post-prandial glucose (PPG) levels in normal-weight and overweight subjects. Additionally, post-prandial insulin (PPI) levels as well as the safety and tolerability of gum acacia were assessed. 35 healthy subjects aged 25 - 60 years, body mass index 18.5 kg/m<sup>2</sup> - 29.9 kg/m<sup>2</sup>, received one treatment of 20 g, 40 g, or 0 g of AG each. Glucose and insulin values were determined at -15 min and prior to the intake (time “0”) as well as 15, 30, 45, 60, 90 120, and 180 min after the “0 min” blood draw. The mean PPG levels were lower (34% in D1 group, p = 0.003;35% in D2 group, p = 0.005) than in the NT group. PPI concentration was statistically significantly lower at all time points except baseline in both treatment groups compared to NT groups. Global benefit and tolerability were rated as “very good” or “good” by 100% of subjects in the treatment groups. This study provides robust evidence of the significant benefits of AG consumption on PPG and PPI levels in healthy subjects. Moreover, very good tolerability was demonstrated.
基金supported by the National Natural Science Foundation of China(51603105,51773099,51390483,91527306,21620102005)the Program for Changjiang Scholars and Innovative Research Team in University(IRT1257)
文摘For type 1 and advanced type 2 diabetic patients, insulin replacement therapy with simulating on-demand prandial and basal insulin secretion is the best option for optimal glycemic control. However, there is no insulin delivery system yet could mimic both controlled basal insulin release and rapid prandial insulin release in response to real-time blood glucose changes. Here we reported an artificial insulin delivery system, mimicking physiological basal and prandial insulin secretion, to achieve real-time glycemic control and reduce risk of hypoglycemia. A phenylboronic acid(PBA)/galactosyl-based glucose-responsive insulin delivery system was prepared with insulin-loaded micelles embedded in hydrogel matrix. At the hyperglycemic state, both the hydrogel and micelles could swell and achieve rapid glucose-responsive release of insulin, mimicking prandial insulin secretion.When the glucose level returned to the normal state, only the micelles partially responded to glucose and still released insulin gradually. The hydrogel with increased crosslinking density could slow down the diffusion speed of insulin inside, resulting in controlled release of insulin and simulating physiological basal insulin secretion. This hydrogel-micelle composite insulin delivery system could quickly reduce the blood glucose level in a mouse model of type 1 diabetes, and maintain normal blood glucose level without hypoglycemia for about 24 h. This kind of glucose-responsive hydrogel-micelle composite may be a promising candidate for delivery of insulin in the treatment of diabetes.
文摘目的 分析德谷门冬双胰岛素、基础-餐时胰岛素短期强化治疗对新诊断2型糖尿病(T2DM)患者血糖控制的影响。方法 选取60例新诊断T2DM患者为研究对象,依据随机数字法分为对照组(30例,德谷门冬双胰岛素治疗)、研究组(30例,基础-餐时胰岛素短期强化治疗)。对比两组患者的血糖指标[糖化血红蛋白(HbA1c)、空腹血糖(FPG)和餐后2 h血糖(2 h PBG)],血糖控制情况(血糖达标时间、血糖波动水平)和低血糖发生率,治疗效果。结果 两组治疗前HbA1c、FPG和2 h PBG水平对比无显著差异(P>0.05);治疗后,研究组HbA1c(6.08±0.76)%、FPG(5.71±0.59)mmol/L和2 h PBG(7.53±0.96)mmol/L比对照组的(8.19±1.14)%、(6.86±0.84)mmol/L、(9.38±1.33)mmol/L低,差异具有统计学意义(P<0.05)。研究组患者血糖达标时间为(6.95±1.61)d、血糖波动为(2.25±0.35)mmol/L、夜间低血糖发生率为0;对照组患者血糖达标时间为(8.26±1.56)d、血糖波动为(3.12±0.68)mmol/L、夜间低血糖发生率为20.00%;研究组患者的血糖达标时间、血糖波动水平和低血糖发生率均显著低于对照组,差异具有统计学意义(P<0.05)。研究组患者的治疗总有效率(100.00%)显著高于对照组(80.00%),差异具有统计学意义(P<0.05)。结论 对于新诊断T2DM患者来说,基础-餐时胰岛素短期强化治疗相对于德谷门冬双胰岛素疗效较好,值得推广。
